Viridian Therapeutics, Inc. VRDN Other Income (Expense)
Other Income (Expense) at other companies
Other financials
Where this comes from
Reported directly by Viridian Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.
The official record: Viridian Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viridian Therapeutics, Inc.'s other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viridian Therapeutics, Inc.'s other income (expense)?
- Viridian Therapeutics, Inc. (VRDN) reported other income (expense) of $11.27M in Q1 2026.
- How has Viridian Therapeutics, Inc.'s other income (expense) changed year-over-year?
- Viridian Therapeutics, Inc.'s other income (expense) increased by 62.0% year-over-year, from $6.95M to $11.27M.
- What is the long-term trend for Viridian Therapeutics, Inc.'s other income (expense)?
- Over 4 years (2021 to 2025), Viridian Therapeutics, Inc.'s other income (expense) has grown at a 185.0% compound annual growth rate (CAGR), from $315K to $20.79M.
- What does other income (expense) mean?
- Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.